Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Other financing activities (2019 - 2021)

Quarterly results put Other financing activities at -$1.4 million for Q1 2021, down 41.4% from a year ago — trailing twelve months through Dec 2021 was -$1.4 million (down 148.94% YoY), and the annual figure for FY2022 was $500000.0, up 135.36%.

Armata Pharmaceuticals has reported Other financing activities over the past 3 years, most recently at -$1.4 million for Q1 2021.

  • Other financing activities reached -$1.4 million in Q1 2021 per ARMP's latest filing, down from $432000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $432000.0 in Q4 2020 and bottomed at -$1.4 million in Q1 2021.
  • Median Other financing activities over the past 3 years was -$1.0 million (2019), compared with a mean of -$745500.0.
  • The largest annual shift saw Other financing activities changed 0.0% in 2020 before it tumbled 41.4% in 2021.
  • Over 3 years, Other financing activities stood at -$1.0 million in 2019, then surged by 143.2% to $432000.0 in 2020, then crashed by 427.31% to -$1.4 million in 2021.
  • Business Quant data shows Other financing activities for ARMP at -$1.4 million in Q1 2021, $432000.0 in Q4 2020, and -$1.0 million in Q1 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2021 -1.41 Mn
Mar 31, 2021 -1.41 Mn
Dec 31, 2020 432,000.00
Dec 31, 2020 432,000.00
Mar 31, 2020 -1.00 Mn
Mar 31, 2020 -1.00 Mn
Mar 31, 2019 -1.00 Mn
Mar 31, 2019 -1.00 Mn